Dihexa's '10 million times more potent than BDNF' claim, fact-checked

What did @fxe3_jones actually say?

Here's the awkward truth: @fxe3_jones didn't say anything about Dihexa. The transcript is song lyrics, likely from a trending audio clip playing over what appears to be a peptide promotion video. The actual claims live entirely in the caption, not in any spoken content. That matters, because a lot of the viral spread of this video is driven by text people read, not arguments anyone actually made out loud.

The caption claims Dihexa is "orally active," "brain-penetrating," and "10 million times more potent than BDNF in stimulating synapse formation." It also gestures at neurogenesis and synaptic enhancement before the caption cuts off. So we're fact-checking a caption, not a creator's reasoned argument. That's worth keeping in mind when assessing how much weight this content deserves.

Does the science back this up?

Partially, in rats. The 10-million-times-more-potent figure comes from real research, but it's being applied in a way that strips out almost every important caveat. The original work by McCoy et al. (2013, Journal of Pharmacology and Experimental Therapeutics) found Dihexa outperformed BDNF in a rat model of cognitive impairment, using behavioral and in vitro synaptogenesis assays. That's legitimately interesting preclinical data.

The problem is the jump from "interesting rat data" to implied human cognitive enhancement. Dihexa works by potentiating hepatocyte growth factor (HGF) signaling at the MET receptor, which does play a role in neuroplasticity. But HGF/MET signaling is also involved in oncogenesis. There are no published Phase I, II, or III human clinical trials for Dihexa as of this writing. The oral bioavailability claim is supported in animal models (Bhatt et al., 2017), but human pharmacokinetics are essentially unknown. Calling something "orally active" in humans based on rodent data is a significant extrapolation.

What did they get wrong (or right)?

The 10-million-times figure is technically sourced, so points for that. McCoy et al. did report that Dihexa was approximately 10 million-fold more potent than BDNF in a cell-based synaptogenesis assay. That's not fabricated. But context matters enormously here, and the caption provides none of it.

What the caption gets wrong, or at least dangerously incomplete:

• "Brain-penetrating" is supported in rodents, not demonstrated in humans with any published data.
• "Significantly promotes neuroplasticity" in humans is unproven. Neuroplasticity in a rat hippocampal slice is not the same thing as meaningful cognitive change in a person.
• The MET receptor pathway Dihexa activates has known associations with tumor growth and proliferation. This is not a minor footnote. Fang et al. (2005, Cancer Research) documented MET's role in oncogenesis. The caption has zero mention of this.
• The caption implies cognitive enhancement as a practical outcome. There is no human trial supporting this claim.

The framing that this peptide is ready for optimization use is, at best, premature. At worst, it encourages people to self-administer a compound with uncharacterized human safety data and a plausible oncogenic mechanism.

What should you actually know?

Dihexa is one of the more scientifically interesting compounds in the peptide space, which is exactly why the hype around it deserves more scrutiny, not less. The preclinical data from Washington State University's research group is genuinely compelling. But compelling preclinical data has a long, humbling history of not translating to humans. Most drugs fail in translation. Peptides are no exception.

If you're interested in peptides that actually have some human data behind them, the bar looks very different from what this caption implies. Semax, for example, has Soviet-era and some more recent Russian clinical data. GHK-Cu has wound healing literature. None of these are FDA-approved for cognitive enhancement, but at least the human exposure data exists in some form.

Dihexa has none of that. It is a research compound. Anyone selling it for human use is operating in a legal gray area at best. If you see it offered on a telehealth platform without a serious informed consent process that includes the oncogenic risk discussion, that's a red flag worth taking seriously.